Spyre Retitles Its Lead Risk Factor After A $378.0 Million Stock Sale, Runway Now Reaches 2029
The biotech's new quarterly report drops going-concern wording as R&D spending nearly doubles and its rheumatic disease drug is shelved.
Spyre Therapeutics, a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease, rewrote its lead risk factor in a 10-Q filed Tuesday, dropping the going-concern language after an October stock sale with net proceeds of about $378.0 million. The company now says its cash lasts into the second half of 2029.
From warning to a plain funding need
The prior quarter's 10-Q headed its lead risk factor "we will not be able to continue as a going concern if we are unable to raise additional capital." The new filing retitles it "we will need to raise additional capital to fund our operations."
The October offering sold 4,735,295 shares at $85.00 each, including 617,647 shares from the underwriters' option, which they exercised in full. Net proceeds were about $378.0 million after roughly $24.5 million of underwriting discounts and other costs.
As of September 30, Spyre held $1.1 billion in cash, cash equivalents and marketable securities. The company's earnings release put pro forma cash at $1,467.9 million, counting the offering and $18.0 million of October share sales through its at-the-market program.
Spending nearly doubles
Research and development expense rose 97% to $89.2 million in the third quarter, from $45.2 million a year earlier. The prior quarter's figure was $65.5 million, against $40.1 million. Net loss for the third quarter was $96.1 million, versus $11.2 million a year earlier, when a $40.3 million other-income item on contingent value rights helped the comparison.
A new dermatology line accounts for $11.9 million of the quarter's research spending, up from nothing a year earlier, as clinical work began on SPY072 for hidradenitis suppurativa, a chronic skin condition. Rheumatology spending rose to $19.4 million from $6.8 million.
Spyre said in November it will not advance SPY072 in rheumatic diseases. The drug met neither primary goal in its psoriatic arthritis and axial spondyloarthritis studies, and its rheumatoid arthritis benefit fell short of the company's internal bar.
Stock sales fund the pipeline
Spyre has no approved products and has paid for its pipeline almost entirely by selling stock. An April offering at $62.00 a share netted about $435.2 million, and the October sale came at $85.00.
The at-the-market program, which lets the company sell shares into the market through an agent, has sold a further 200,111 shares for $18.0 million since September 30. That leaves $451.6 million available as of November 3.
Topline results from the combination portion of the SKYLINE ulcerative colitis trial are expected in the third quarter of 2027. Spyre plans to take SPY072 as a monotherapy into pivotal hidradenitis suppurativa studies in 2027.
The company's own estimate carries a caveat: its assumptions may prove wrong, and it could use up its capital sooner than it expects.
Sources
- 10-Q Filing — Spyre Therapeutics (SYRE) — SEC EDGAR
- 10-Q Filing — Spyre Therapeutics (SYRE), Q2 FY2026 filed 2026-08-04 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, spyre-20260930xexx991pd.htm) — Spyre Therapeutics, filed 2026-11-03 — SEC EDGAR
